,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['mbc', 'bcsm', 'breast']
practice changing study: t-dxd significantly improved both pfs &amp; os in her2 low mbc. wonderful news for patients &amp; the field. adcs changing how we treat breast cancer. excellent presentation by dr. shanu modi plenary #bcsm 
Medical Oncologist, MGH, Harvard Medical School. Interested in cool science, technology, patient stories, and therapies against cancer.